EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease

Patryk Lipiński iD, Dariusz Rokicki iD, Karolina Chwiałkowska iD, Michał Ciborowski iD, Joanna Godzień iD, Aleksandra Jezela-Stanek iD, Urszula Korotko iD, Mirosław Kwaśniewski, Magdalena Niemira iD, Paulina Szymańska-Rożek, Małgorzata Syczewska iD, Anna Tylki-Szymańska iD

Life · 16.03.2026 · 16 (3) · 485

DOI: 10.3390/life16030485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 16.03.2026. Verfasst von Patryk Lipiński und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Medical Center of Postgraduate Education, 01-813 Warsaw, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gaucher disease (GD) is a lysosomal storage disorder caused by deficiency of β-glucocerebrosidase, leading to accumulation of glucocerebroside in lysosomes. Type 1 GD is most commonly associated with the N370S mutation and lacks neurological involvement, whereas the neuronopathic forms (types 2 and 3), frequently linked to L444P homozygosity, present with progressive neurological symptoms. Enzyme replacement therapy (ERT) effectively treats visceral manifestations but does not cross the blood–brain barrier and, therefore, does not improve neurological outcomes. Ambroxol, a plant-derived mucolytic agent, has been shown to act as a pharmacological chaperone capable of increasing residual enzyme activity and crossing into the central nervous system, with reports suggesting neurological benefit in L444P homozygotes.

Methods

We evaluated 13 patients with type 3 GD (L444P/L444P homozygotes) who received ambroxol at 10 mg/kg/day for one year as part of a clinical trial. All participants had been on long-term ERT with stable biomarker levels (chitotriosidase, glucosylsphingosine [Lyso-GL1]) and hematological parameters. Neurological symptoms were assessed using the modified Severity Scoring Tool (mSST). Biomarkers and hematologic indices were monitored throughout the study.

Results

Ambroxol treatment resulted in a reduction in severity or complete resolution of selected neurological symptoms in several patients.

Conclusions

In patients with type 3 GD receiving stable ERT, ambroxol demonstrated beneficial effects on neurological symptom expression. Some improvement was observed in biomarkers; the activity of chitotrosidase and concentration of lyso-Gl1 decreased. These findings support the therapeutic potential of ambroxol as an adjunctive treatment for neuronopathic Gaucher disease.

Schlagwörter

Stichwörter der Autor:innen

Gaucher disease neuronopathic formGaucher disease type 3ambroxolneurological symptoms

Autor:innen und Institutionen

  • Department of Pediatrics, Medical Center of Postgraduate Education, 01-813 Warsaw, Poland.
  • Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
  • Laboratory of Computational Molecular Medicine, Clinical Research Centre, Medical University of Białystok, 15-089 Białystok, Poland.
  • Metabolomics and Proteomics Laboratory, Clinical Research Centre, Medical University of Białystok, 15-089 Białystok, Poland.
  • Department of Medical Biochemistry, Medical University of Białystok, 15-089 Białystok, Poland.
  • Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.

ORCID-Profile: Patryk Lipiński, Dariusz Rokicki, Karolina Chwiałkowska, Michał Ciborowski, Joanna Godzień, Aleksandra Jezela-Stanek, Urszula Korotko, Magdalena Niemira, Małgorzata Syczewska, Anna Tylki-Szymańska

Förderung

  • Medical Research Agency

Zitieren

APA

Lipiński, P., Rokicki, D., Chwiałkowska, K., Ciborowski, M., Godzień, J., Jezela-Stanek, A., Korotko, U., Kwaśniewski, M., Niemira, M., Szymańska-Rożek, P., Syczewska, M., & Tylki-Szymańska, A. (2026). Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease. Life, 16(3), 485. https://doi.org/10.3390/life16030485

Vancouver

Lipiński P, Rokicki D, Chwiałkowska K, Ciborowski M, Godzień J, Jezela-Stanek A, et al. Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease. Life. 2026;16(3):485. doi:10.3390/life16030485

BibTeX
@article{Lipiski2026,
  author = {Lipiński, Patryk and Rokicki, Dariusz and Chwiałkowska, Karolina and Ciborowski, Michał and Godzień, Joanna and Jezela-Stanek, Aleksandra and Korotko, Urszula and Kwaśniewski, Mirosław and Niemira, Magdalena and Szymańska-Rożek, Paulina and Syczewska, Małgorzata and Tylki-Szymańska, Anna},
  title = {Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {485},
  doi = {10.3390/life16030485}
}
Kostenlos starten →